These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

864 related articles for article (PubMed ID: 28088907)

  • 1. Tofacitinib, an Oral Janus Kinase Inhibitor: Perspectives in Dermatology.
    Kostovic K; Gulin SJ; Mokos ZB; Ceovic R
    Curr Med Chem; 2017 May; 24(11):1158-1167. PubMed ID: 28088907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
    Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
    J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral tofacitinib: a promising treatment in atopic dermatitis, alopecia areata and vitiligo.
    Vu M; Heyes C; Robertson SJ; Varigos GA; Ross G
    Clin Exp Dermatol; 2017 Dec; 42(8):942-944. PubMed ID: 29034491
    [No Abstract]   [Full Text] [Related]  

  • 4. JAK inhibitors in dermatology: The promise of a new drug class.
    Damsky W; King BA
    J Am Acad Dermatol; 2017 Apr; 76(4):736-744. PubMed ID: 28139263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Janus kinase inhibitors in dermatology: A systematic review.
    Shreberk-Hassidim R; Ramot Y; Zlotogorski A
    J Am Acad Dermatol; 2017 Apr; 76(4):745-753.e19. PubMed ID: 28169015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK-inhibitors in dermatology: current evidence and future applications.
    Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
    J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical Janus kinase inhibitors: A review of applications in dermatology.
    Hosking AM; Juhasz M; Mesinkovska NA
    J Am Acad Dermatol; 2018 Sep; 79(3):535-544. PubMed ID: 29673776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of janus kinase inhibitors in the treatment of alopecia areata.
    Triyangkulsri K; Suchonwanit P
    Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofacitinib for the treatment of moderate-to-severe psoriasis.
    Chiricozzi A; Faleri S; Saraceno R; Bianchi L; Buonomo O; Chimenti S; Chimenti MS
    Expert Rev Clin Immunol; 2015 Apr; 11(4):443-55. PubMed ID: 25666451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib.
    Cheng MW; Kehl A; Worswick S; Goh C
    J Drugs Dermatol; 2018 Jul; 17(7):800-803. PubMed ID: 30005104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasis.
    Di Lernia V; Bardazzi F
    Drug Des Devel Ther; 2016; 10():533-9. PubMed ID: 26889081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.
    Craiglow BG; King BA
    JAMA Dermatol; 2015 Oct; 151(10):1110-2. PubMed ID: 26107994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Janus kinase inhibitors for skin disorders].
    Solimani F; Ghoreschi K
    Dermatologie (Heidelb); 2024 Oct; 75(10):781-790. PubMed ID: 39212722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK-STAT signaling pathway inhibition: a role for treatment of various dermatologic diseases.
    Kahn J; Deverapalli SC; Rosmarin D
    Semin Cutan Med Surg; 2018 Sep; 37(3):198-208. PubMed ID: 30215638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus kinase inhibitors: An innovative treatment for alopecia areata.
    Park H; Yu DA; Kwon O
    J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tofacitinib Represses the Janus Kinase-Signal Transducer and Activators of Transcription Signalling Pathway in Keratinocytes.
    Srivastava A; Ståhle M; Pivarcsi A; Sonkoly E
    Acta Derm Venereol; 2018 Aug; 98(8):772-775. PubMed ID: 29738047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aggression behaviour induced by oral administration of the Janus-kinase inhibitor tofacitinib, but not oclacitinib, under stressful conditions.
    Fukuyama T; Tschernig T; Qi Y; Volmer DA; Bäumer W
    Eur J Pharmacol; 2015 Oct; 764():278-282. PubMed ID: 26164790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib for the treatment of alopecia areata and variants in adolescents.
    Craiglow BG; Liu LY; King BA
    J Am Acad Dermatol; 2017 Jan; 76(1):29-32. PubMed ID: 27816292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers.
    Jabbari A; Nguyen N; Cerise JE; Ulerio G; de Jong A; Clynes R; Christiano AM; Mackay-Wiggan J
    Exp Dermatol; 2016 Aug; 25(8):642-3. PubMed ID: 27119625
    [No Abstract]   [Full Text] [Related]  

  • 20. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients.
    Liu LY; Craiglow BG; Dai F; King BA
    J Am Acad Dermatol; 2017 Jan; 76(1):22-28. PubMed ID: 27816293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.